Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ivy Alwell

Registered Nurse, Psychiatric/Mental Health, Adult Hillsboro, MO Clinical Nurse Specialist

NPI 1477684009 CMS profile 10800854

4 Hickory Ridge Rd Ste 600, Hillsboro, MO 63050

Open in the dashboard

General payments

$5,928

327 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ivy Alwell of Hillsboro, MO is reported in the CMS Open Payments database as having received $5,928 across 327 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Registered Nurse, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $214 5
2024 General $1,124 43
2023 General $1,864 123
2022 General $1,570 86
2021 General $1,156 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivy Alwell
  • Registered Nurse, Psychiatric/Mental Health, Adult median
  • Middle half of Registered Nurse, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Ivy Alwell were reported at $214. Among 96 Registered Nurse, Psychiatric/Mental Health, Adult profiles paid that year, the median was $121 and the middle half received between $39 and $265.

Show as a table
Year Ivy Alwell Registered Nurse, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,156 $108 $31–$328 $132
2022 $1,570 $99 $22–$306 $149
2023 $1,864 $99 $43–$313 $160
2024 $1,124 $119 $30–$319 $164
2025 $214 $121 $39–$265 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,406 102 payments
  2. Supernus Pharmaceuticals, Inc. $756 25 payments
  3. ITI, Inc. $529 29 payments
  4. Vanda Pharmaceuticals Inc. $423 26 payments
  5. Otsuka America Pharmaceutical, Inc. $313 15 payments
  6. Janssen Pharmaceuticals, Inc $302 19 payments
  7. Lundbeck LLC $290 15 payments
  8. Axsome Therapeutics, Inc. $274 10 payments
  9. Sunovion Pharmaceuticals Inc. $210 12 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $179 9 payments
  11. Other $1,246 65 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,830 321 payments
  2. Education $98 6 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,406 102 payments
  2. CAPLYTA $529 29 payments
  3. Qelbree Viloxazine Hydrochloride $524 12 payments
  4. FANAPT $406 24 payments
  5. SPRAVATO $302 19 payments
  6. REXULTI Psychiatry $290 15 payments
  7. REXULTI Psychiatry $277 13 payments
  8. Auvelity $274 10 payments
  9. HETLIOZ $256 14 payments
  10. QELBREE Psychology $232 13 payments
  11. Other $2,510 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

771

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$75,277

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

14.5%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fanapt Iloperidone Brand 18 $45,544
Rexulti Brexpiprazole Brand 12 $20,549
Vilazodone Hcl Generic 11 $787
Mirtazapine Generic 31 $759
Fluoxetine Hcl Generic 88 $744
Bupropion Xl Bupropion Hcl Brand 26 $622
Quetiapine Fumarate Generic 46 $613
Lamotrigine Generic 59 $561
Olanzapine Generic 31 $511
Aripiprazole Generic 29 $482

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$1,374

Medicare's payments for the services billed

Medicare patients

20

Average age 66

Services billed

34

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 70%
Arthritis 55%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $524
$524 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $130
$130 18 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $83
  • Lundbeck LLC $18
$102 12 —
VRAYLAR
  • AbbVie, Inc. $60
$60 — —
CAPLYTA
  • ITI, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

327 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record